TACSTD2 and adenocarcinoma: In contrast to TROP2, CEACAM5 displayed a negative correlation with AR in CRPC–adenocarcinoma and was expressed in all NEPC clusters, suggesting that CEACAM5 is an actionable target for non-AR-driven disease (Fig. 4D) (49).